SAFC added 20 raw materials to its PharmaGrade portfolio and announced an expansion of its Irvine, Scotland manufacturing plant.
SAFC, the custom manufacturing and services business unit of Sigma-Aldrich, announced that it added of 20 raw materials for biopharmaceutical manufacturing to its PharmaGrade portfolio and expects the line of buffers, amino acids, and specialty chemicals to double in size by the end of 2013.
Products in the PharmaGrade portfolio are provided with full documentation of manufacturing history, are compliant with either GMP (Good Manufacturing Practice) standards or the SAFC Elite Quality grade standards, and are quality assurance reviewed and released, according to a company announcement.
The company also announced an expansion of its manufacturing plant in Irvine, Scotland to include large-scale production of bulk dry power media and reagents. Designed to support the expanding needs of the European and Asia Pacific market, SAFC’s Irvine facility expansion will result in redundant manufacturing capabilities in conjunction with SAFC’s existing dry powder media facility in Lenexa, Kan.
SAFC will construct a purpose-built Animal Component Free (ACF) dry powder media manufacturing facility to complement the existing liquid cell culture media, buffers, and reagents capabilities in Irvine. Ground breaking for the new facility is expected to commence in March 2013 and should be manufacturing-ready in Q1 of 2014.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.